Temasek Holdings’s Alexion Pharmaceuticals ALXN Stock Holding History

Temasek Holdings’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-616,630	Closed	-$60M	–	59
2018 Q4	$60M	Sell	616,630 -610,000	-50%	-$72.1M	0.41%	36
2018 Q3	$171M	Sell	1,226,630 -278,695	-19%	-$35M	0.99%	23
2018 Q2	$187M	Hold	1,505,325	–	–	0.98%	24
2018 Q1	$168M	Hold	1,505,325	–	–	0.92%	24
2017 Q4	$180M	Hold	1,505,325	–	–	1.11%	22
2017 Q3	$211M	Buy	1,505,325 +52,403	+4%	+$7.12M	1.23%	15
2017 Q2	$177M	Buy	1,452,922 +226,292	+18%	+$26.3M	1.14%	17
2017 Q1	$149M	Hold	1,226,630	–	–	1.11%	17
2016 Q4	$150M	Hold	1,226,630	–	–	1.2%	15
2016 Q3	$150M	Hold	1,226,630	–	–	1.22%	13
2016 Q2	$143M	Hold	1,226,630	–	–	1.12%	15
2016 Q1	$171M	Hold	1,226,630	–	–	1.35%	15
2015 Q4	$234M	Hold	1,226,630	–	–	1.78%	11
2015 Q3	$192M	Hold	1,226,630	–	–	1.82%	13
2015 Q2	$222M	Buy	+1,226,630	New	+$212M	1.39%	15

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Temasek Holdings's ALXN Position: Q1 2019 in Review

Temasek Holdings sold out of Alexion Pharmaceuticals (ALXN) in Q1 2019, closing a stake of 616,630 shares — an estimated $60M sold.

Temasek Holdings first reported a position in ALXN in Q2 2015 and held it in 15 quarters. The position peaked at $234M in Q4 2015. 612 funds tracked by Wall St. Rank hold ALXN as of Q1 2019.

Temasek Holdings reported no remaining Alexion Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Temasek Holdings sold 616,630 Alexion Pharmaceuticals shares in Q1 2019, an estimated $60M.
Temasek Holdings first reported a position in Alexion Pharmaceuticals in Q2 2015 and held it in 15 quarters.
Temasek Holdings's Alexion Pharmaceuticals position peaked at $234M in Q4 2015.
612 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2019.

Based on Temasek Holdings's 13F filing for Q1 2019, filed 15 May 2019.